Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?

Kim LauperLianne Kearsley-FleetJames B GallowayKath D Watsonnull nullKimme L HyrichMark Lunt

Published in: Rheumatology (Oxford, England) (2023)

The risk of serious infections does not appear to be influenced by the line of therapy in patients with RA. However, the risk of tuberculosis seems to be more frequent during the initial lines of treatment or prior to 2009.

Keyphrases

mycobacterium tuberculosis
rheumatoid arthritis
pulmonary tuberculosis
disease activity
ankylosing spondylitis
mesenchymal stem cells
hiv aids
adverse drug